No abstract available.
Prostatic Hyperplasia*

No abstract available.
Prostatic Hyperplasia

No abstract available.
Prostatic Hyperplasia*

No abstract available.
Hyperplasia* ; Prostate* ; Prostatic Hyperplasia ; Prostatic Neoplasms

The study was made on 42 benign prostatic hyperplasia patients. The results showed that after one month therapy by traditional medication, symptoms scoring index IPSS reduced from 21.0 to 11.71 (p<0.05). The flow of urinary increased from 4.56ml/s to 8.98ml/s (p<0.05). Residual urine volume reduced from 16.52ml to 8.35ml (p<0.05). The therapeutic outcomes by the extract of "Than khi hoan gia giam" were classified as follows: Good in 23 cases (54.8%), Moderate in 15 cases (35.7%), Poor in 4 cases (9.5%).
Prostatic Hyperplasia ; Therapeutics ; Prostatic Hyperplasia ; Medicine, Traditional

No abstract available.
Laser Coagulation* ; Prostatic Hyperplasia*

No abstract available.
Apoptosis* ; Prostate* ; Prostatic Hyperplasia*

82 benign prostatic hyperplasia (BPH) patients (between 50 and 90 years old) have undergone endoscopic surgeries with Stolz machine. Results: after 18 months, there was no death, problems of electrical knife during operation: 1.25%, post-operation complications: bleeding: 0, infection: 2 cases, and gastric hemorrhage 1 case. Late complications: dysuria 9 cases, no one developing urethral stenosis. Endoscopic surgery is superior to traditional procedures, and it needs broader application.
Therapeutics ; Endoscopy ; Prostatic Hyperplasia

30 patients with benign prostatic hypertrophy, aged 69.2  8.58, at Hue Central Hospital were studied from November 2001 to April 2002. Disuria was the main symptoms, accounted for 60%. Ultrasound showed that 100% of cases had large size of the tumors with mean weight of 80.3  58.1g. Pre-operative indices were: bladder residual volume 207.5  139ml, urine voided time 43.7  19.4 seconds, voided volume 84.2  47.5 ml, mean flow of urine 2.5  1.93ml/second, and post-operative indices were 84.2  72.3ml, 40.1  21.8 seconds, 118.3  46.7 ml, 4.5  3.34 ml/second respectively
Prostatic Hyperplasia ; Urodynamics ; ultrasonography

The literature has suggested that alpha-receptor blockade may have therapeutic value in treating the symptoms of patients with benign prostatic hypertrophy. Terazosin is an alpha-1 adrenergic blocking agent approved by the FDA for the treatment of benign prostatic hypertrophy. We treated 30 patients with symptomatic benign prostatic hypertrophy in double- blind fashion using terazosin and placebo. In placebo group, mean total symptom score was decreased from 9.8 to 7.7 (p <0.0001), but was statistically significant in only obstructive symptom score. Changes in maximal and mean urinary flow rates were from 9.8 to 10.3 and from 4.9 to 5.3, respectively, but there was no statistical significance (p>0.05). In terazosin group, the symptom score changes in obstructive and irritative were from 6.1 to 3.3 and from 4.5 to 5.9 (p <0.0001), respectively, and changes in maximal and mean urinary flow rates were from symptoms 8.7 to 10.2 and from 4.2 to 5.9, respectively (p<0.0001). There were significant improvements in all parameters in terazosin group when compared with placebo group (p<0.05). It was concluded that terazosin is beneficial for treatment of obstructive symptoms in patients with benign prostatic hypertrophy.
Humans ; Prostatic Hyperplasia*